February 18, 2021 04:13 AM ESTUpdated 06:22 AM

A month after multi-billion dollar Novartis deal, BeiGene follows up with 'reverse' deal

Nicole DeFeudis

Editor

Just over a month after striking a deal with Novartis to bring its PD-1 antibody tislelizumab stateside, China-based BeiGene is making a similar play in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

A month after multi-billion dollar Novartis deal, BeiGene follows up with 'reverse' deal

Nicole DeFeudis

Editor

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

Vertex makes money from sickle cell therapy Casgevy

Sanofi reveals positive data for BTK inhibitor from $3.7B Principia takeover

Sana narrows focus again to zero in on diabetes and autoimmune disease

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

A month af­ter mul­ti-bil­lion dol­lar No­var­tis deal, BeiGene fol­lows up with 're­verse' deal

Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

A month after multi-billion dollar Novartis deal, BeiGene follows up with 'reverse' deal